It's Time For a Quick Look at Haleon's Fundamentals.

By Emilio Sanchez • Wednesday, December 06 11:03 • Permanent Link

Join us for a quick overview of Haleon, a Household & Personal Products company whose shares moved 0.8% today. Here are some facts about the stock that should help you see the bigger picture:

HLN has an average analyst rating of buy and is -10.37% away from its mean target price of $9.21 per share
Its trailing earnings per share (EPS) is $0.34
Haleon has a trailing 12 month Price to Earnings (P/E) ratio of 24.3 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $0.44 and its forward P/E ratio is 18.8
The company has a Price to Book (P/B) ratio of 4.64 in contrast to the S&P 500's average ratio of 2.95
Haleon is part of the Consumer Discretionary sector, which has an average P/E ratio of 22.96 and an average P/B of 4.24
HLN has reported YOY quarterly earnings growth of 5.1% and gross profit margins of 0.6%
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Weybridge, the United Kingdom.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.